VANCOUVER, Jan. 3 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V: PRX), a
leader in advancing novel, targeted protein toxin therapeutics for the
treatment of cancer and other proliferative diseases, today announced positive
final results from its Phase 1 study evaluating PRX302 in patients with benign
prostatic hyperplasia (BPH), a common condition among the aging male
population. The trial results indicate that PRX302 is safe and well tolerated
and shows very promising signs of therapeutic activity for the treatment of
BPH.
